Skip to main content

Concurrent Use of Opioids and Benzodiazepines (COB)

CBE ID
3389
Endorsed
New or Maintenance
Is Under Review
No
Measure Description

The percentage of individuals >=18 years of age with concurrent use of prescription opioids and benzodiazepines during the measurement year.

A lower rate indicates better performance.

  • Measure Type
    Electronic Clinical Quality Measure (eCQM)
    Level Of Analysis
    Data dictionary not attached
    No
    Numerator

    The number of individuals from the denominator with concurrent use of opioids and benzodiazepines for >=30 cumulative days during the measurement year.

    Denominator

    The denominator includes individuals >=18 years of age with >=2 prescription claims for opioid medications on different dates of service and with >=15 cumulative days’ supply during the measurement year. Individuals with cancer, sickle cell disease, or in hospice are excluded.

    Exclusions

    Individuals with cancer, sickle cell disease, or in hospice at any point during the measurement year are excluded from the denominator.

    All information required to stratify the measure results
    Off
    All information required to stratify the measure results
    Off
    Testing Data Sources
  • Risk adjustment approach
    Off
    Risk adjustment approach
    Off
    Conceptual model for risk adjustment
    Off
    Conceptual model for risk adjustment
    Off
  • Most Recent Endorsement Activity
    Endorsed Patient Safety Spring Cycle 2021
    Initial Endorsement
    Next Planned Maintenance Review
    Patient Safety Spring 2025
    Endorsement Status
    Last Updated
  • Detailed Measure Specifications
    No
    Logic Model
    Off
    Impact and Gap
    No
    Feasibility assessment methodology and results
    No
    Address health equity
    No
    Measure’s use or intended use
    No
    508 Compliance
    Off